BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 26637878)

  • 1. 2-Deoxy-D-glucose Sensitizes Cancer Cells to Barasertib and Everolimus by ROS-independent Mechanism(s).
    Zhelev Z; Ivanova D; Aoki I; Saga T; Bakalova R
    Anticancer Res; 2015 Dec; 35(12):6623-32. PubMed ID: 26637878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docosahexaenoic Acid Sensitizes Leukemia Lymphocytes to Barasertib and Everolimus by ROS-dependent Mechanism Without Affecting the Level of ROS and Viability of Normal Lymphocytes.
    Zhelev Z; Ivanova D; Lazarova D; Aoki I; Bakalova R; Saga T
    Anticancer Res; 2016 Apr; 36(4):1673-82. PubMed ID: 27069145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the Pentose-phosphate Pathway Selectively Sensitizes Leukemia Lymphocytes to Chemotherapeutics by ROS-independent Mechanism.
    Zhelev Z; Ivanova D; Bakalova R; Aoki I; Higashi T
    Anticancer Res; 2016 Nov; 36(11):6011-6020. PubMed ID: 27793928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Cytotoxicity of Melatonin and New-generation Anticancer Drugs Against Leukemia Lymphocytes But Not Normal Lymphocytes.
    Zhelev Z; Ivanova D; Bakalova R; Aoki I; Higashi T
    Anticancer Res; 2017 Jan; 37(1):149-159. PubMed ID: 28011485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib.
    Ivanova D; Zhelev Z; Lazarova D; Getsov P; Bakalova R; Aoki I
    Anticancer Res; 2018 Mar; 38(3):1407-1414. PubMed ID: 29491065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Targeting of Cancerous Mitochondria and Suppression of Tumor Growth Using Redox-Active Treatment Adjuvant.
    Bakalova R; Semkova S; Ivanova D; Zhelev Z; Miller T; Takeshima T; Shibata S; Lazarova D; Aoki I; Higashi T
    Oxid Med Cell Longev; 2020; 2020():6212935. PubMed ID: 33204397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Alpha-tocopheryl Succinate on the Cytotoxicity of Anticancer Drugs Towards Leukemia Lymphocytes.
    Ivanova D; Zhelev Z; Zlateva G; Lazarova D; Yaneva Z; Panovska R; Aoki I; Bakalova R
    Anticancer Res; 2022 Jan; 42(1):547-554. PubMed ID: 34969764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol Modulates the Redox-status and Cytotoxicity of Anticancer Drugs by Sensitizing Leukemic Lymphocytes and Protecting Normal Lymphocytes.
    Ivanova D; Zhelev Z; Semkova S; Aoki I; Bakalova R
    Anticancer Res; 2019 Jul; 39(7):3745-3755. PubMed ID: 31262901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of glutamate cysteine ligase activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-D-glucose.
    Andringa KK; Coleman MC; Aykin-Burns N; Hitchler MJ; Walsh SA; Domann FE; Spitz DR
    Cancer Res; 2006 Feb; 66(3):1605-10. PubMed ID: 16452219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
    Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
    Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Deoxy-D-glucose enhances sensitivity of human histiocytic lymphoma U937 cells to apoptosis induced by tumor necrosis factor.
    Halicka HD; Ardelt B; Li X; Melamed MM; Darzynkiewicz Z
    Cancer Res; 1995 Jan; 55(2):444-9. PubMed ID: 7812976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Deoxy-D-glucose Restore Glucocorticoid Sensitivity in Acute Lymphoblastic Leukemia via Modification of N-Linked Glycosylation in an Oxygen Tension-Independent Manner.
    Leni Z; Ćwiek P; Dimitrova V; Dulcey AS; Zamboni N; Simillion C; Rossi G; Leibundgut K; Arcaro A
    Oxid Med Cell Longev; 2017; 2017():2487297. PubMed ID: 28814986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate.
    Nakagawa H; Hasumi K; Woo JT; Nagai K; Wachi M
    Carcinogenesis; 2004 Sep; 25(9):1567-74. PubMed ID: 15090467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.
    Gao M; Gao L; Tao Y; Hou J; Yang G; Wu X; Xu H; Tompkins VS; Han Y; Wu H; Zhan F; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2014 Jun; 46(6):484-91. PubMed ID: 24801128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    Denlinger CE; Rundall BK; Jones DR
    J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glycosylation inhibitor 2-deoxy-D-glucose sensitizes oral cancer cells to TRAIL-induced apoptosis].
    Xu J; Huang Y; Li Y; Pu L; Xia F; Jiang C; Liu H; Jiang Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):524-7. PubMed ID: 23644112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of 2-deoxy-D-glucose on the cytotoxicity of cyclosporin A in vitro.
    Ouyang Z; Cao W; Zhu S; Liu X; Zhong Z; Lai X; Xiao C; Jiang S; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):2814-20. PubMed ID: 25976221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).
    Keizer RJ; Zandvliet AS; Beijnen JH; Schellens JH; Huitema AD
    Invest New Drugs; 2012 Aug; 30(4):1519-30. PubMed ID: 21626115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.